[Does the use of metoprolol-succinate in patients with chronic heart failure lead to a higher efficacy in treatment without causing additional costs?].
Sonntag
F
F
f.j.sonntag@t-online.de
Schöffski
O
O
Hass
B
B
D000319:Adrenergic beta-Antagonists / Q000191:economics* / Q000627:therapeutic use; D017046:Cost Savings / Q000706:statistics & numerical data; D016527:Drug Costs / Q000706:statistics & numerical data*; D005858:Germany; D006333:Heart Failure / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D008790:Metoprolol / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D009313:National Health Programs / Q000191:economics*; D010343:Patient Admission / Q000191:economics*
D000319:Adrenergic beta-Antagonists; D008790:Metoprolol